secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRA LIFESCIENCES HOLDINGS CORP (IART)
CIK:        0000917520
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0000917520-26-000034
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Integra LifeSciences Appoints Stuart Essig as President and CEO, Replacing Mojdeh Poul
--------------------------------------------------------------------------------

- Stuart Essig appointed President and CEO effective May 1, 2026; he also remains Chairman of the Board.
- Mojdeh Poul departed as President and CEO and from the Board effective April 30, 2026; she receives $566,526 lump sum.
- Essig receives $1,075,000 base salary, 125% target bonus, and initial equity awards totaling $8 million in RSUs and options.
- Michael McBreen appointed Chief Commercial Officer with base salary $660,000 and $1,000,000 one-time equity award.
- Essig previously served as Integra's CEO from 1997 to 2012 and as Executive Chairman from February 2024 to June 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/917520/000091752026000034/0000917520-26-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/917520/000091752026000034/iart-20260430.htm
  HTML page:      https://secwatch.observer/filing/0000917520-26-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer